Literature DB >> 12191632

Mechanisms underlying epigenetically mediated gene silencing in cancer.

Stephen B Baylin1.   

Abstract

It has become apparent that epigenetically mediated alterations, which establish heritable abnormalities in gene expression, are a fundamental feature of human cancer. The best studied of these changes are aberrant gene silencing events which involve transcriptional inactivation associated with abnormally methylated promoter region CpG islands. A most important aspect of understanding this change, which can cause loss of key gene function, concerns dissection of the molecular mechanisms that mediate the transcriptional repression and those responsible for establishing the abnormal methylation and associated chromatin events. This chapter reviews the progress in these arenas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12191632     DOI: 10.1016/s1044-579x(02)00053-6

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  26 in total

1.  MethySYBR, a novel quantitative PCR assay for the dual analysis of DNA methylation and CpG methylation density.

Authors:  Pang-Kuo Lo; Hanano Watanabe; Pi-Chun Cheng; Wei Wen Teo; Xiaohui Liang; Pedram Argani; Ji Shin Lee; Saraswati Sukumar
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

2.  CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.

Authors:  Mark L McCleland; Kathryn Mesh; Edward Lorenzana; Vivek S Chopra; Ehud Segal; Colin Watanabe; Benjamin Haley; Oleg Mayba; Murat Yaylaoglu; Florian Gnad; Ron Firestein
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

Review 3.  Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors:  Kelly Faulk; Lia Gore; Todd Cooper
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

4.  Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.

Authors:  Serena Racanicchi; Chiara Maccherani; Concetta Liberatore; Monia Billi; Vania Gelmetti; Maddalena Panigada; Giovanni Rizzo; Clara Nervi; Francesco Grignani
Journal:  EMBO J       Date:  2005-02-24       Impact factor: 11.598

5.  Epigenetic inactivation of the SFRP1 gene in esophageal squamous cell carcinoma.

Authors:  Ying Meng; Qing-Gang Wang; Jun-Xiong Wang; Sheng-tao Zhu; Yue Jiao; Peng Li; Shu-tian Zhang
Journal:  Dig Dis Sci       Date:  2011-05-13       Impact factor: 3.199

Review 6.  An overview of epigenetics and chemoprevention.

Authors:  Yi-Wen Huang; Chieh-Ti Kuo; Kristen Stoner; Tim H-Y Huang; Li-Shu Wang
Journal:  FEBS Lett       Date:  2010-11-05       Impact factor: 4.124

7.  Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.

Authors:  Nicole M Anders; Jianyong Liu; Teresia Wanjiku; Hugh Giovinazzo; Jianya Zhou; Ajay Vaghasia; William G Nelson; Srinivasan Yegnasubramanian; Michelle A Rudek
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-03-21       Impact factor: 3.205

8.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 9.  Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening.

Authors:  Sung Whan An; Nam Kyu Kim; Hyun Cheol Chung
Journal:  Yonsei Med J       Date:  2009-06-23       Impact factor: 2.759

Review 10.  Targeting cell death in tumors by activating caspases.

Authors:  Sarah H MacKenzie; A Clay Clark
Journal:  Curr Cancer Drug Targets       Date:  2008-03       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.